ATE501250T1 - Mutantes follistatin-polypeptid - Google Patents

Mutantes follistatin-polypeptid

Info

Publication number: ATE501250T1
Authority: AT; Austria
Prior art keywords: cys; integer; activity; amino acid; follistatin
Prior art date: 2004-04-15

Application number

AT05734002T

Other languages

English (en)

Inventor

Kunihiro Tsuchida

Tatsuya Murakami

Original Assignee

Techno Network Shikoku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-15

Filing date

2005-04-15

Publication date

2011-03-15

2005-04-15 Application filed by Techno Network Shikoku Co Ltd filed Critical Techno Network Shikoku Co Ltd

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE501250T1 publication Critical patent/ATE501250T1/de

Links

102000016970 Follistatin Human genes 0.000 title abstract 4
108010014612 Follistatin Proteins 0.000 title abstract 4
229920001184 polypeptide Polymers 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
230000000694 effects Effects 0.000 abstract 4
102000005606 Activins Human genes 0.000 abstract 2
108010059616 Activins Proteins 0.000 abstract 2
102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 2
108010056852 Myostatin Proteins 0.000 abstract 2
239000000488 activin Substances 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Hematology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Obesity (AREA)
Neurology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)

AT05734002T 2004-04-15 2005-04-15 Mutantes follistatin-polypeptid ATE501250T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2004120023		2004-04-15
JP2004355293A JP4688483B2 (ja)	2004-04-15	2004-12-08	フォリスタチン変異体ポリペプチド
PCT/JP2005/007662 WO2005100563A1 (ja)	2004-04-15	2005-04-15	フォリスタチン変異体ポリペプチド

Publications (1)

Publication Number	Publication Date
ATE501250T1 true ATE501250T1 (de)	2011-03-15

Family

ID=35150007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05734002T ATE501250T1 (de)	2004-04-15	2005-04-15	Mutantes follistatin-polypeptid

Country Status (10)

Country	Link
US (1)	US7867973B2 (de)
EP (1)	EP1748069B1 (de)
JP (1)	JP4688483B2 (de)
KR (1)	KR20070039483A (de)
CN (1)	CN1993463B (de)
AT (1)	ATE501250T1 (de)
AU (1)	AU2005233474B2 (de)
CA (1)	CA2562885A1 (de)
DE (1)	DE602005026796D1 (de)
WO (1)	WO2005100563A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
WO2008030367A2 (en) *	2006-09-01	2008-03-13	The General Hospital Corporation	Selective myostatin inhibitors
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN102131822A (zh)	2008-06-26	2011-07-20	阿塞勒隆制药公司	进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
DK2318028T3 (da)	2008-06-26	2020-05-04	Acceleron Pharma Inc	Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR20120049214A (ko)	2009-06-08	2012-05-16	악셀레론 파마 인코포레이티드	발열성 지방세포를 증가시키는 방법
AU2010315245B2 (en)	2009-11-03	2016-11-03	Acceleron Pharma Inc.	Methods for treating fatty liver disease
WO2013149258A2 (en)	2012-03-30	2013-10-03	Charles Drew University of Medicine and Science	Compositions and methods for treating or preventing metabolic syndrome disorders
ES2715710T3 (es) *	2013-01-25	2019-06-05	Shire Human Genetic Therapies	Folistatina en el tratamiento de la distrofía muscular de Duchenne
EA202090632A1 (ru)	2014-06-04	2020-07-31	Акселерон Фарма Инк.	Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
US10010498B2 (en)	2014-06-04	2018-07-03	Acceleron Pharma Inc.	Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
JP2016131541A (ja) *	2015-01-20	2016-07-25	学校法人藤田学園	トランスジェニック非ヒト哺乳動物及びその用途
EP3274457A4 (de)	2015-03-26	2018-08-08	Acceleron Pharma Inc.	Follistatin-assoziierte fusionsproteine und verwendungen davon
EP3418744A4 (de) *	2016-02-19	2018-12-26	Konica Minolta, Inc.	Durch quantitative beurteilung von versuchstierproben charakterisiertes nicht-klinisches prüfverfahren
EP3765601A1 (de) *	2018-03-16	2021-01-20	Immusoft Corporation	Genetisch manipulierte b-zellen zur sezernierung von follistatin und verfahren zur verwendung davon zur behandlung von follistatinbedingten krankheiten, leiden, störungen und zur erhöhung des muskelwachstums und der muskelkraft
US12522647B2 (en)	2019-01-22	2026-01-13	Paul Scherrer Institut	Beta-arrestin mutants
JP7445640B2 (ja) *	2019-03-01	2024-03-07	神戸天然物化学株式会社	ミオスタチンスプライスバリアント由来タンパク質によるミオスタチンシグナル阻害とその利用
CA3094859A1 (en) *	2020-10-01	2022-04-01	Entos Pharmaceuticals Inc.	Proteolipid vesicles formulated with fusion associated small transmembrane proteins
WO2025157262A1 (en) *	2024-01-25	2025-07-31	Sichuan Real & Best Biotech Co., Ltd.	Nucleic acids encoding follistatin and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182375A (en) *	1987-08-28	1993-01-26	The Salk Institute For Biological Studies	DNA encoding follistatin
DK0690873T3 (da) *	1993-03-19	2003-09-29	Univ Johns Hopkins Med	Vækstdifferentieringsfaktor-8
US5545616A (en) *	1994-09-22	1996-08-13	Genentech, Inc.	Method for predicting and/or preventing preterm labor
US6656475B1 (en)	1997-08-01	2003-12-02	The Johns Hopkins University School Of Medicine	Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) *	1997-08-01	2005-05-10	The Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en)	1998-02-19	2002-04-09	Metamorphix International, Inc.	Myostatin multimers
US6004937A (en) *	1998-03-09	1999-12-21	Genetics Institute, Inc.	Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
MXPA01007366A (es)	1999-01-21	2002-06-04	Metamorphix Inc	Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
TR200400621T2 (tr)	1999-07-20	2004-08-23	Pharmexa A/S	GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
EP1226249A2 (de) *	1999-11-03	2002-07-31	ZymoGenetics, Inc.	Follistatin-verwandtes protein zfsta4
US7368534B2 (en)	2000-01-18	2008-05-06	Orico Limited	Myostatin and mimetics thereof
GB0100762D0 (en)	2001-01-11	2001-02-21	Smithkline Beecham Plc	Novel use
US6852693B2 (en) *	2002-02-07	2005-02-08	Blm Group	Compositions and methods for promoting lipid mobilization in humans
EP1572909A4 (de) *	2002-02-21	2007-06-06	Wyeth Corp	Protein mit follistatindomäne
JP5355053B2 (ja)	2008-09-19	2013-11-27	住友化学株式会社	有害生物防除用組成物及び有害生物の防除方法

2004
- 2004-12-08 JP JP2004355293A patent/JP4688483B2/ja not_active Expired - Fee Related
2005
- 2005-04-15 DE DE602005026796T patent/DE602005026796D1/de not_active Expired - Lifetime
- 2005-04-15 AT AT05734002T patent/ATE501250T1/de not_active IP Right Cessation
- 2005-04-15 WO PCT/JP2005/007662 patent/WO2005100563A1/ja not_active Ceased
- 2005-04-15 KR KR1020067023962A patent/KR20070039483A/ko not_active Abandoned
- 2005-04-15 US US11/578,408 patent/US7867973B2/en not_active Expired - Fee Related
- 2005-04-15 EP EP05734002A patent/EP1748069B1/de not_active Expired - Lifetime
- 2005-04-15 AU AU2005233474A patent/AU2005233474B2/en not_active Ceased
- 2005-04-15 CA CA002562885A patent/CA2562885A1/en not_active Abandoned
- 2005-04-15 CN CN2005800198613A patent/CN1993463B/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2005100563A1 (ja)	2005-10-27
US7867973B2 (en)	2011-01-11
AU2005233474B2 (en)	2010-12-09
JP4688483B2 (ja)	2011-05-25
DE602005026796D1 (de)	2011-04-21
EP1748069B1 (de)	2011-03-09
KR20070039483A (ko)	2007-04-12
CN1993463B (zh)	2012-10-03
AU2005233474A1 (en)	2005-10-27
EP1748069A1 (de)	2007-01-31
JP2005323584A (ja)	2005-11-24
EP1748069A4 (de)	2008-04-30
CA2562885A1 (en)	2005-10-27
US20080090755A1 (en)	2008-04-17
CN1993463A (zh)	2007-07-04

Legal Events

Date	Code	Title	Description
2011-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE501250T1 (de)	2011-03-15	Mutantes follistatin-polypeptid
IN2014CN02050A (de)	2015-05-29
MX2009005655A (es)	2009-10-21	Composiciones y usos de un polipeptido alfa-amilasa del bacilo de la especie 195.
NZ594755A (en)	2013-12-20	Cyclosporin analogues for preventing or treating hepatitis c infection
TW200710209A (en)	2007-03-16	Polishing composition
BRPI0414062B8 (pt)	2021-05-25	uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv
NZ594457A (en)	2013-06-28	Compositions and methods for the delivery of oxygen
BR0211750A (pt)	2004-10-13	Agente antiviral
MX2007003812A (es)	2007-05-24	Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc).
EP1801206A4 (de)	2009-01-14	Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
TW200726842A (en)	2007-07-16	Mutant glucose dehydrogenase
IL173158A0 (en)	2006-06-11	Polypeptide having an improved cytosine deaminase activity
MX2008009493A (es)	2008-10-03	Peptido novedoso y uso del mismo.
WO2009047992A1 (ja)	2009-04-16	Ｕｄｐ－グルクロン酸転移酵素およびそれをコードするポリヌクレオチド
MX2009006638A (es)	2009-07-02	Agente para erradicar helicobacter pylori que tiene actividad inhibidora sobre la secrecion de acido gastrico.
IL175319A0 (en)	2006-09-05	Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
MX2007000334A (es)	2007-06-25	Polipeptido.
WO2007062526A8 (en)	2007-08-30	Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
PL1791858T3 (pl)	2010-09-30	Zmodyfikowane białko kapsydowe VP1 z parwowirusa B19
MY139016A (en)	2009-08-28	PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF ß-ADRENERGIC RECEPTOR KINASE 1
SE0003815D0 (sv)	2000-10-18	Struktur som motverkar biologisk påväxt i akvatisk miljö
IN2009DN06580A (de)	2015-07-24
WO2006103101A3 (en)	2007-02-01	MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
PH12013502021A1 (en)	2015-12-14	Platelet aggregation inhibitor composition
TW200720281A (en)	2007-06-01	A method of manufacturing an organic silicon compound that contains a methacryloxy group or an acryloxy group